Advertisement
U.S. Markets open in 47 mins

DBV Technologies S.A. (DBVT)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Visitors trend2W10W9M
0.7392-0.0290 (-3.78%)
At close: 04:00PM EST
0.7387 +0.00 (+0.30%)
Pre-Market: 05:26AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.7682
Open0.7400
Bid0.7001 x 100
Ask0.7749 x 100
Day's Range0.7200 - 0.7738
52 Week Range0.5020 - 2.1400
Volume59,350
Avg. Volume662,093
Market Cap81.827M
Beta (5Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)-0.9100
Earnings DateNov 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • Pharmaceutical Technology

    DBV Technologies’ stock slides as financial woes worsens

    The company reported that it does not have sufficient cash reserves to operate for the next 12 months and can only fund operations into Q1 2025.

  • GlobeNewswire

    DBV Technologies Reports Third Quarter 2024 Financial Results

    Châtillon, France, November 6, 2024 DBV Technologies Reports Third Quarter 2024 Financial Results DBV closes Q3 2024 with a cash balance of $46.4 million; cash runway into Q1 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J200), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2024. The quarterly and nine months financial statements were approved by the Board of Directors on November 6, 2024